DE-CSC/PALO-ALTO-NETWRKS
23.7.2024 15:01:32 CEST | Business Wire | Press release
CSC, an enterprise-class domain registrar and world leader in mitigating domain security, domain name system (DNS), and digital brand threats, today announces a technical collaboration with Palo Alto Networks to boost domain security for users of Palo Alto Network’s Cortex XSOAR, XSIAM, and XPANSE solutions and for CSC's domain registrar clients. Under this collaboration, CSC will use domain name, DNS, and secure sockets layer (SSL) portfolio data—in conjunction with intelligence and capabilities within Cortex—to contextualize risks and facilitate the remediation of threats.
This new integration pack for our CSCDomainManager℠ application programming interface (API) is now available for download via the Cortex marketplace. As part of the relationship, joint Cortex and CSC clients can also benefit from a complimentary, defined package of domain name and URL phishing takedowns that target corporate domain name portfolios. This will help secure clients against threat vectors targeting their brands online—working to fortify their overall security posture.
“Given the increasing threats faced by organizations and their consumers due to brand impersonation and other DNS security issues, we're excited to extend CSC's robust data sets and solutions to our clients conveniently through their existing Cortex products. Going after malicious actors at their root via takedowns and ensuring proper DNS security to prevent hijacking and other risks are powerful proactive steps to prevent damaging security incidents,” says Andrew Scott, director of product at Palo Alto Networks.
“CSC detects domain threats, online brand and DNS abuse, and fraud to protect companies from cyberattacks caused by compromised or fraudulent domains,” says Mark Calandra, president of CSC's Digital Brand Services division. “Our inclusion in the Cortex marketplace is a testament to our capabilities and in-depth knowledge of the domain security landscape and boosts the visibility of our services by seamlessly integrating into the workflow of users focused on optimizing their cybersecurity posture.”
“In today’s ever-evolving cybersecurity landscape, integrating robust domain security and brand protection measures is not just a necessity, but a strategic imperative. Our collaboration with Palo Alto Networks exemplifies our commitment to delivering a comprehensive security posture that address the blended threats our clients face,” says Ihab Shraim, chief technology officer at CSC’s Digital Brand Services. “By leveraging advanced intelligence and capabilities, we empower businesses to proactively defend against domain-related cyber threats and ensure the integrity of their digital brand presence.”
Key benefits of the CSC and Cortex integration include:
- Cortex XSOAR: Automates threat detection and incident response, simplifying management of domain-related security.
- Cortex XSIAM: Analyzes data to identify vulnerabilities and enhances proactive threat mitigation strategies.
- Cortex XPANSE: Provides visibility into and secures internet-facing assets, improving detection of vulnerable domains.
- CSC Enhanced Domain Registrar Security: Strengthens defenses against hijacking, phishing and cyber threats. Implements continuous monitoring to protect against evolving domain security threats.
This partnership underscores the commitment of both CSC and Palo Alto Networks to deliver state-of-the-art security solutions, ensuring the safety and integrity of digital assets for their clients.
About CSC
CSC is the trusted security and threat intelligence provider of choice for the Forbes Global 2000 and the 100 Best Global Brands (Interbrand®) with focus areas in domain security and management, along with digital brand and fraud protection. As global companies make significant investments in their security posture, our DomainSec℠ platform can help them understand cybersecurity oversights that exist and help them secure their online digital assets and brands. By leveraging CSC’s proprietary technology, companies can solidify their security posture to protect against cyber threat vectors targeting their online assets and brand reputation, helping them avoid devastating revenue loss. CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—with a multidimensional view of various threats outside the firewall targeting specific domains. Fraud protection services that combat phishing in the early stages of attack round out our solutions. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.
About Palo Alto Networks
Palo Alto Networks is the world's cybersecurity leader. We innovate to outpace cyberthreats, so organizations can embrace technology with confidence. We provide next-gen cybersecurity to thousands of customers globally, across all sectors. Our best-in-class cybersecurity platforms and services are backed by industry-leading threat intelligence and strengthened by state-of-the-art automation. Whether deploying our products to enable the Zero Trust Enterprise, responding to a security incident, or partnering to deliver better security outcomes through a world-class partner ecosystem, we're committed to helping ensure each day is safer than the one before. It's what makes us the cybersecurity partner of choice.
At Palo Alto Networks, we're committed to bringing together the very best people in service of our mission, so we're also proud to be the cybersecurity workplace of choice, recognized among Newsweek's Most Loved Workplaces (2023, 2022, 2021), with a score of 100 on the Disability Equality Index (2023, 2022), and HRC Best Places for LGBTQ+ Equality (2022). For more information, visit www.paloaltonetworks.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723899433/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
